Literature DB >> 16183691

Syncope following cardioverter defibrillator implantation in patients with spontaneous syncopal monomorphic ventricular tachycardia.

Mauricio Abello1, José L Merino, Rafael Peinado, Mariana Gnoatto, Miguel A Arias, Mar Gonzalez-Vasserot, José A Sobrino.   

Abstract

AIMS: We sought to determine the incidence, mechanisms, and time to syncope recurrence in patients with spontaneous syncopal monomorphic ventricular tachycardia (SyMVT) treated with an implantable cardiac defibrillator (ICD). METHODS AND
RESULTS: Incidence and causes of syncope following ICD implantation in consecutive patients (n=26) with spontaneous SyMVT were compared with those found in consecutive patients (n=50) with spontaneous non-syncopal monomorphic ventricular tachycardia (NSyMVT). Patients with SyMVT had a higher incidence of syncope (46% patients) than those with NSyMVT (2% patients) at 31+/-21 and 34+/-23 months follow-up, respectively (hazard ratio, 0.19; 95% confidence interval, 0.04-0.42; P=0.0001). Among the former, four patients (15%) had non-arrhythmic syncope and eight patients had arrhythmic syncope (31%), which was associated with either ICD proarrhythmia (seven episodes of VT acceleration or VF degeneration by ATP or low/high-energy shocks in three patients) or spontaneous VT and VF (five episodes in five patients). Median time to the first arrhythmic syncope was 376 days. Arrhythmic syncope presented after a first non-syncopal VT recurrence in six patients (75%).
CONCLUSION: Syncope following ICD implantation is common in patients with SyMVT in contrast to patients with NSyMVT. Late syncope presentation supports reassessment of driving restrictions in this setting.

Entities:  

Mesh:

Year:  2005        PMID: 16183691     DOI: 10.1093/eurheartj/ehi500

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  4 in total

Review 1.  Recommendations for driving after implantable cardioverter defibrillator implantation and the use of a wearable cardioverter defibrillator : Different viewpoints around the world.

Authors:  Mona Cooper; Theresa Berent; Johann Auer; Robert Berent
Journal:  Wien Klin Wochenschr       Date:  2020-05-20       Impact factor: 1.704

2.  Cardiovascular magnetic resonance-GUIDEd management of mild to moderate left ventricular systolic dysfunction (CMR GUIDE): Study protocol for a randomized controlled trial.

Authors:  Joseph B Selvanayagam; Trent Hartshorne; Laurent Billot; Suchi Grover; Graham S Hillis; Werner Jung; Henry Krum; Sanjay Prasad; Andrew D McGavigan
Journal:  Ann Noninvasive Electrocardiol       Date:  2017-01-24       Impact factor: 1.468

3.  Beta-blocker therapy is associated with a lower incidence of syncope due to fast ventricular tachycardias among implantable cardioverter-defibrillator patients with left ventricular dysfunction: results from a multicenter study.

Authors:  Javier Jiménez-Candil; Ignasi Anguera; Olga Durán; Jesús Hernández; Javier Fernández-Portales; José Luis Moríñigo; Ana Martín; Paolo Dallaglio; Loreto Bravo; Andrea di Marco; Pedro Luis Sánchez
Journal:  J Interv Card Electrophysiol       Date:  2018-03-20       Impact factor: 1.900

4.  Non-invasive programmed stimulation to identify high-risk patients with implanted cardioverter defibrillator (the NIPS-ICD study): study protocol for a randomized controlled trial.

Authors:  Piotr Futyma; Marian Futyma; Piotr Kułakowski
Journal:  Trials       Date:  2016-01-27       Impact factor: 2.279

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.